World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
29609
World Ranking
15954
National Ranking
8029

James M. Reuben publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James M. Reuben sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 383 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James M. Reuben D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James M. Reuben sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James M. Reuben is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on oncology and cancer-related biomedical fields.

The main fields of study in their work include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their research spans several subfields, particularly:

  • Oncology
  • Cancer Research
  • Immunology
  • Biomedical Engineering
  • Pulmonary and Respiratory Medicine

Key topics addressed in James M. Reuben's publications involve:

  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Chemokine receptors and signaling

The researcher has published extensively in several venues including:

  • Cancer Research
  • Breast Cancer Research
  • Cancers
  • PLoS ONE
  • Clinical Cancer Research

Frequent collaborators with whom James M. Reuben has co-authored work include:

  • Naoto T. Ueno
  • Evan N. Cohen
  • Hui Gao
  • Savitri Krishnamurthy
  • Debu Tripathy

Selected recent papers authored or co-authored by James M. Reuben include:

  • "A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer," 2020, Breast Cancer Research
  • "A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System," 2022, Cancers
  • "EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer," 2022, Science Advances
  • "EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy," 2020, PLoS ONE
  • "Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy," 2020, Journal of Translational Medicine

Best Publications

  • Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

    Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck

  • Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

    Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis

  • Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia

    Jorge R. Quesada;James M Reuben;John T. Manning;Evan M. Hersh

  • Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

    Elise Olsen;Madeleine Duvic;Arthur Frankel;Youn Kim

  • Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

    Antoni Ribas;Luis H. Camacho;Gabriel Lopez-Berestein;Dmitri Pavlov

  • Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms

    Charles S. Cleeland;Gary J. Bennett;Robert Dantzer;Patrick M. Dougherty

  • Soluble TNF-α receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight

    William T. Shearer;James M. Reuben;Janet M. Mullington;Nicholas J. Price

  • Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study

    Gabriel Lopez-Berestein;Victor Fainstein;Roy Hopfer;Kapil Mehta

  • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

    Alessandra Ferrajoli;Bang-Ning Lee;Ellen J. Schlette;Susan M. O'Brien

  • Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions

    J. P. Cata;H. Wang;V. Gottumukkala;J. Reuben

  • Nuclear factor–κB and STAT3 are constitutively active in CD138+cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

    Alok C. Bharti;Shishir Shishodia;James M. Reuben;Donna Weber

  • Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

    Luis E Fayad;Michael J. Keating;James M. Reuben;Susan O'Brien

  • A cytokine-based neuroimmunologic mechanism of cancer-related symptoms

    Bang-Ning Lee;Robert Dantzer;Keith E. Langley;Gary J. Bennett

  • Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy

    Lajos Pusztai;Tito R Mendoza;James M. Reuben;Monica M. Martinez

  • Treatment of hairy cell leukemia with recombinant alpha-interferon.

    JR Quesada;EM Hersh;J Manning;J Reuben

  • Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.

    E. Andreopoulou;L. Y. Yang;K. M. Rangel;J. M. Reuben

  • Inflammatory breast cancer biology: the tumour microenvironment is key

    Bora Lim;Wendy A. Woodward;Xiaoping Wang;James M. Reuben

  • Breast Cancer Metastasis: Challenges and Opportunities

    Jing Lu;Patricia S. Steeg;Janet E. Price;Savitri Krishnamurthy

  • Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2

    C. F. LeMaistre;Mansoor N. Saleh;Timothy M. Kuzel;Francine Foss

  • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Commentary

    Thomas S. Lin;Alessandra Ferrajoli;Bang-Ning Lee;Ellen J. Schlette

Frequent Co-Authors

Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Wendy A. Woodward
Wendy A. Woodward The University of Texas MD Anderson Cancer Center
Savitri Krishnamurthy
Savitri Krishnamurthy The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Charles S. Cleeland
Charles S. Cleeland The University of Texas MD Anderson Cancer Center
William T. Shearer
William T. Shearer Baylor College of Medicine
Anthony Lucci
Anthony Lucci The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering Medicine in the USA, a variety of online degrees offer flexible and affordable entry points into healthcare careers. Many students start by exploring health administration degrees online, which prepare graduates for roles in hospital management, medical offices, and public health organizations.

For those aiming for leadership roles, pursuing one of the cheapest mha programs online can be a strategic move. An online Master of Healthcare Administration (MHA) degree is designed to deepen your knowledge of health systems, finance, and policy while maintaining a flexible learning schedule.

Clinical professionals may also consider advancing their qualifications through dnp online programs cheap, which focus on nursing practice at the doctoral level. Pharmacists and those interested in medication management should explore reputable online pharmacy programs for affordable pathways to a pharmacy doctorate.

Exploring these online options can help you find a career path that balances academic ambitions, affordability, and the flexibility needed to succeed in the fast-changing world of healthcare.

Best Scientists Citing James M. Reuben

Trending Scientists

Recently Published Articles